Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
8
×
Tags
clinical trials
8
×
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
8
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
boston blog main
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
boston top stories
fda
glaxosmithkline
amgen
novartis
abbvie
biogen
bristol-myers squibb
cancer
cancer immunotherapy
europe blog main
europe top stories
medical devices
What
roundup
8
×
bio
days
biotech
cancer
drug
lung
news
pricing
abbvie’s
according
acquisitions
advanced
advantages
ahead
akcea
alliance
announced
arrival
august
award
bar
biofourmis
black
brings
bristol
bucks
busy
buy
calls
cases
celebrate
centers
ceo
chance
changing
cigarettes
collabs
color
companies
Language
unset
8
×
Current search:
roundup
×
photo
×
" new york top stories "
×
unset
×
" clinical trials "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
4 years ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
